RIP1 Kinase Drives Macrophage-Mediated Adaptive Immune Tolerance in Pancreatic Cancer.
Wang, W., Marinis, J.M., Beal, A.M., Savadkar, S., Wu, Y., Khan, M., Taunk, P.S., Wu, N., Su, W., Wu, J., Ahsan, A., Kurz, E., Chen, T., Yaboh, I., Li, F., Gutierrez, J., Diskin, B., Hundeyin, M., Reilly, M., Lich, J.D., Harris, P.A., Mahajan, M.K., Thorpe, J.H., Nassau, P., Mosley, J.E., Leinwand, J., Kochen Rossi, J.A., Mishra, A., Aykut, B., Glacken, M., Ochi, A., Verma, N., Kim, J.I., Vasudevaraja, V., Adeegbe, D., Almonte, C., Bagdatlioglu, E., Cohen, D.J., Wong, K.K., Bertin, J., Miller, G.(2018) Cancer Cell 34: 757-774.e7
- PubMed: 30423296 
- DOI: 10.1016/j.ccell.2018.10.006
- Primary Citation of Related Structures:  
6HHO - PubMed Abstract: 
Pancreatic ductal adenocarcinoma (PDA) is characterized by immune tolerance and immunotherapeutic resistance. We discovered upregulation of receptor-interacting serine/threonine protein kinase 1 (RIP1) in tumor-associated macrophages (TAMs) in PDA. To study its role in oncogenic progression, we developed a selective small-molecule RIP1 inhibitor with high in vivo exposure ...